In 2022, the global life sciences industry generated about 78 million metric tons of CO2e from Scope 1 and 2 emissions, equal to 1.2% of total global industrial emissions. The rest of the footprint shows up in Scope 3 supply chains, water withdrawals, and hazardous waste totals from areas like API production. This dataset ties those emissions and resource pressures to the measurable cuts companies report, including progress on diversion, recycling, and efficiency in manufacturing and labs.
Key Takeaways
- In 2022, the global life sciences industry generated approximately 78 million metric tons of CO2 equivalent from Scope 1 and 2 emissions, accounting for 1.2% of total global industrial emissions
- Pharmaceutical manufacturing facilities in Europe reduced their Scope 1 GHG emissions by 25% per unit of product between 2015 and 2020, driven by electrification initiatives
- 65% of the largest life sciences companies have set science-based targets for net-zero emissions by 2050, aligned with the SBTi
- 92% of life sciences companies publish annual sustainability reports with GRI standards
- 60% invest >1% R&D budget in green chemistry for sustainable molecules
- Novartis' sustainability dashboard tracks 50+ KPIs, integrated into executive pay
- Global life sciences supply chains sourced 45% raw materials sustainably certified in 2022
- 70% of API suppliers in India/China audited for ESG, with 25% de-risked post-audit
- Pharma spent $150 billion on sustainable procurement in 2023, up 18% YoY
- Life sciences industry generated 5.2 million tons of hazardous waste in 2022, 60% from API production
- Pharma packaging waste totals 1.1 million tons/year globally, with 70% plastic-based
- 85% of life sciences companies recycle >50% non-hazardous waste, averaging 75% diversion rate
- Global life sciences industry withdrew 1.2 billion cubic meters of water in 2022, with 45% from high-stress basins
- Pharma manufacturing uses 20-50 liters of water per vaccine dose, targeted for 30% reduction by WHO standards
- 68% of life sciences companies have water stewardship goals, with 25% achieving 20%+ reduction since 2015
In 2022, the life sciences sector emitted 78 million tons CO2e from Scope 1 and 2.
Related reading
- Sustainability In IndustrySustainability In The Industrial Industry Statistics
- Sustainability In IndustrySustainability In The Food Manufacturing Industry Statistics
- Sustainability In IndustrySustainability In The Agricultural Industry Statistics
- Sustainability In IndustrySustainability In The Petroleum Industry Statistics
01 · Category
Emissions and Climate Impact30 stats
01
In 2022, the global life sciences industry generated approximately 78 million metric tons of CO2 equivalent from Scope 1 and 2 emissions, accounting for 1.2% of total global industrial emissions
02
Pharmaceutical manufacturing facilities in Europe reduced their Scope 1 GHG emissions by 25% per unit of product between 2015 and 2020, driven by electrification initiatives
03
65% of the largest life sciences companies have set science-based targets for net-zero emissions by 2050, aligned with the SBTi
04
In the US biotech sector, Scope 3 emissions from supply chains constitute 85-95% of total GHG footprint, primarily from API production in Asia
05
AstraZeneca achieved a 50% reduction in absolute Scope 1 and 2 emissions since 2015 baseline through renewable energy procurement
06
The life sciences industry's average carbon intensity per revenue dollar was 0.15 tons CO2e in 2021, down 12% from 2019
07
72% of pharma companies report using carbon pricing internally, averaging $25 per ton CO2e to drive decarbonization
08
Novartis reduced its GHG emissions intensity by 35% from 2010-2022 by optimizing HVAC systems in labs
09
Global life sciences R&D facilities emit 15% of sector's total Scope 2 emissions due to energy-intensive equipment like centrifuges
10
Pfizer procured 100% renewable electricity for its operations in 2022, avoiding 1.2 million tons CO2e annually
11
The industry-wide refrigerant leakage contributes 8% to Scope 1 emissions, with HFCs being phased out under Kigali Amendment
12
Sanofi lowered its carbon footprint by 28% per API kg through process intensification in 2021-2023
13
40% of life sciences emissions stem from fossil fuel-based steam in sterilization processes, targeted for biomass switch
14
Roche's sites achieved 45% renewable energy share, reducing Scope 2 by 120,000 tCO2e in 2022
15
Biotech incubators show 20% higher emissions intensity than pharma due to inefficient lab scaling
16
Johnson & Johnson cut Scope 1 emissions 30% via fuel switching to biogas in manufacturing
17
Average life sciences company has 15-year payback on energy efficiency projects, yielding 25% ROI
18
Gilead Sciences reached 60% GHG reduction target early through supplier engagement on Scope 3
19
EU pharma sector's emissions projected to drop 55% by 2030 under Fit for 55 package compliance
20
Merck KGaA emitted 2.1 million tCO2e in 2022, with 50% from purchased goods/services
21
Life sciences data centers consume 2% of sector energy, with AI models increasing demand 30% yearly
22
Eli Lilly's manufacturing emissions fell 22% YoY in 2022 via continuous manufacturing adoption
23
55% of companies disclose TCFD-aligned climate risks, focusing on water scarcity impacts
24
Biogen's Scope 3 emissions from product use are 70% of total, targeted via patient education
25
Global pharma transport emissions rose 10% post-COVID due to cold chain logistics for vaccines
26
Amgen achieved 25% Scope 1+2 reduction by 2022 via LED retrofits and CHP systems
27
Industry average energy cost savings from decarbonization: 15-20% by 2030 per BCG analysis
28
Regeneron reduced lab emissions 40% through fume hood optimization
29
Vertex Pharma's net-zero roadmap includes 90% renewable heat by 2028
30
Life sciences fugitive emissions from labs average 5% of total, mitigated by gas capture tech
Interpretation
Emissions and Climate Impact Interpretation
The life sciences industry is caught in a race between its carbon-intensive habits and its clever fixes, where the immense, sprawling footprint of its global supply chain is slowly being whittled down by a wave of electrification, relentless efficiency, and corporate commitments that are finally putting their money—about $25 per ton—where their molecules are.
02 · Category
Reporting and Innovation21 stats
01
92% of life sciences companies publish annual sustainability reports with GRI standards
02
60% invest >1% R&D budget in green chemistry for sustainable molecules
03
Novartis' sustainability dashboard tracks 50+ KPIs, integrated into executive pay
04
Pfizer launched 10 green chemistry projects, reducing waste 20% per reaction
05
AI-driven process modeling cuts energy use 25% in simulations per McKinsey
06
Sanofi patented 5 bio-based solvents replacing petrochemicals in 2023
07
Roche's digital twin tech optimizes 15% energy in fermentation processes
08
Gilead's mRNA platform reduces manufacturing waste 50% vs. traditional vaccines
09
AstraZeneca's continuous flow chemistry scales 10x faster with 40% less solvent
10
Merck KGaA's enzyme catalysis replaces metals, cutting costs 30% and waste
11
Biogen's modular bioreactors enable 90% uptime, reducing downtime waste
12
Johnson & Johnson 100% ISSB-aligned disclosures planned for 2024
13
Amgen's gene therapy platform uses 70% less reagents per dose
14
Eli Lilly's sustainability bonds raised $1B for green projects in 2023
15
Regeneron tracks 20 ESG metrics quarterly via ESGdatacom
16
Vertex innovated solvent-free crystallization, saving 100 tons solvent/year/site
17
Lonza's Perfex platform recovers 95% single-use plastics industrially
18
Thermo Fisher's MyGreenLab certified 200+ labs, cutting energy 30%
19
75% companies use ESG ratings from MSCI/S&P, average score 65/100 in life sciences
20
Bayer's carbon capture pilot sequesters 5,000 tCO2e/year from fermentation
21
GSK's AI predicts 80% greener synthetic routes pre-lab
Interpretation
Reporting and Innovation Interpretation
The life sciences industry is rapidly transforming from merely treating patients to treating the planet, with a palpable shift from publishing glossy reports to engineering green molecules and linking executive paychecks directly to measurable planetary health metrics.
03 · Category
Supply Chain Sustainability19 stats
01
Global life sciences supply chains sourced 45% raw materials sustainably certified in 2022
02
70% of API suppliers in India/China audited for ESG, with 25% de-risked post-audit
03
Pharma spent $150 billion on sustainable procurement in 2023, up 18% YoY
04
Novartis' supplier code compliance: 95% of direct suppliers, covering 90% spend
05
Pfizer mapped 80% Tier 2 suppliers for Scope 3 emissions, engaging top 100 for reductions
06
55% of life sciences firms use blockchain for traceability in biotech supply chains
07
Sanofi sustainable palm oil usage: 100% RSPO-certified for excipients
08
Roche reduced supplier deforestation risk to <1% via satellite monitoring
09
Gilead's supplier diversity: 15% spend with minority-owned, sustainability-vetted firms
10
AstraZeneca's cobalt sourcing 100% traceable, no child labor incidents reported
11
Merck KGaA's 85% suppliers assessed on human rights via self-assessments
12
Biogen engaged 200+ suppliers in CDP supply chain program, 60% responding
13
Johnson & Johnson sustainable cotton for medical textiles: 50% organic by 2025 early achievement
14
Amgen's glass vial suppliers 100% recyclable content, reducing virgin material 30%
15
Eli Lilly localized 40% supply chain to reduce transport emissions 15%
16
Regeneron audits 100% high-risk suppliers annually for labor standards
17
Vertex's API supply 75% from EU/US to minimize geopolitical risks
18
Lonza's cell culture media suppliers 90% carbon-neutral certified
19
Thermo Fisher 70% electronics suppliers conflict-mineral free per Dodd-Frank
Interpretation
Supply Chain Sustainability Interpretation
The industry is diligently stitching a more responsible safety net, with audits as its suture, traceability as its thread, and billions in procurement spend as its needle, proving that healing the planet is now fundamental to healing people.
More related reading
04 · Category
Waste and Circular Economy22 stats
01
Life sciences industry generated 5.2 million tons of hazardous waste in 2022, 60% from API production
02
Pharma packaging waste totals 1.1 million tons/year globally, with 70% plastic-based
03
85% of life sciences companies recycle >50% non-hazardous waste, averaging 75% diversion rate
04
Novartis diverted 98% of waste from landfill in 2022 via incineration with energy recovery
05
Single-use plastics in bioprocessing generate 20kg waste per 1000L batch, targeted for reduction
06
Pfizer recycled 92% of manufacturing waste, recovering 250,000 tons materials in 2022
07
EU pharma waste incineration emits 0.5 tons CO2e per ton waste, vs. 1.2 for landfilling
08
Sanofi zero-waste-to-landfill certified 80% sites, processing 400,000 tons waste sustainably
09
65% of lab solvents recoverable via distillation, reducing hazardous waste 40%
10
Roche achieved 95% waste recycling rate, including 50% energy recovery from solvents
11
Gilead reduced packaging waste 25% by switching to recyclable mono-materials
12
AstraZeneca's circular economy program reused 30% plastics in secondary packaging
13
Merck KGaA generated 180,000 tons waste, 70% recycled or recovered in 2022
14
Biogen's biologics waste reduced 35% via on-site autoclave sterilization upgrades
15
Johnson & Johnson diverted 99.5% waste from landfill across 250 sites in 2022
16
Amgen composted 15% organic lab waste, diverting 5,000 tons annually
17
Eli Lilly's waste intensity per product unit down 22% since 2015 via supplier audits
18
Regeneron recycled 88% construction waste in expansions, saving 10,000 tons landfill
19
Vertex zero-waste facilities process 100% e-waste via certified recyclers
20
Pharma solvent waste recycling yields 90% recovery rate, cutting costs 50%
21
Lonza's single-use bioreactor recycling pilot recovered 80% plastics by mass
22
Thermo Fisher reduced lab glass waste 40% via reusable alternatives
Interpretation
Waste and Circular Economy Interpretation
The life sciences industry, while healing humanity, produces a staggering mountain of hazardous and plastic waste, yet a hopeful counter-narrative is emerging as leading companies achieve near-zero landfill rates, slash carbon emissions, and innovate with circular economies—proving that preserving the planet can indeed be part of the prescription.
05 · Category
Water and Resource Efficiency25 stats
01
Global life sciences industry withdrew 1.2 billion cubic meters of water in 2022, with 45% from high-stress basins
02
Pharma manufacturing uses 20-50 liters of water per vaccine dose, targeted for 30% reduction by WHO standards
03
68% of life sciences companies have water stewardship goals, with 25% achieving 20%+ reduction since 2015
04
Novartis recycled 85% of wastewater in its sites, saving 4.5 million m3 annually in 2022
05
Biotech cleanroom cleaning consumes 70% of facility water, with closed-loop systems cutting usage 50%
06
Pfizer's India sites zero-liquid discharge achieved, treating 100% wastewater for reuse
07
Average water intensity in pharma: 4.5 m3 per ton product, down 15% from 2010
08
Sanofi reduced water use by 32% since 2008 baseline through cooling tower optimizations
09
30% of life sciences water risks tied to API synthesis in water-scarce regions like China/India
10
Roche withdrew 22 million m3 water in 2022, with 60% recycled or reused onsite
11
EU pharma zero water pollution directive compliance: 90% sites achieved <1mg/L COD in effluent by 2023
12
Gilead's water replenishment ratio reached 150% in high-risk basins via watershed projects
13
Life sciences cooling processes account for 40% water use, with dry cooling tech saving 90%
14
AstraZeneca's sites use 25% less water per batch via membrane bioreactor tech
15
Merck KGaA's water intensity fell 28% to 3.2 m3/ton from 2010-2022
16
Biogen participates in 15 river basin initiatives, restoring 2 million m3 equivalent annually
17
Johnson & Johnson 2022 water use: 15 billion liters, 75% from municipal sources treated for reuse
18
Amgen's Puerto Rico facility recycles 95% process water, avoiding 1.5 million m3/year withdrawal
19
Eli Lilly achieved 20% water reduction via AI-optimized purification cycles
20
Regeneron’s water use per R&D output down 35% since 2015 via low-flow fixtures
21
Vertex targets 100% water positive by 2030, currently at 120% replenishment rate
22
Global pharma wastewater contains 10-20% pharmaceuticals by volume, risking aquatic toxicity
23
52% of sites use rainwater harvesting, averaging 10% of total supply in tropical regions
24
Lonza reduced water intensity 40% in biologics via single-use tech minimizing cleaning
25
Thermo Fisher sites treat 90% wastewater onsite, reusing 65 million m3 in 2022
Interpretation
Water and Resource Efficiency Interpretation
While the life sciences industry is guzzling over a billion cubic meters of water a year, often from already parched basins, the clever race to recycle, replenish, and redesign—from AI-optimized labs to zero-liquid discharge factories—proves that the sector’s most vital prescription is now for its own environmental health.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Sustainability In The Life Sciences Industry Statistics. Gitnux. https://gitnux.org/sustainability-in-the-life-sciences-industry-statistics
MLA
Kevin O'Brien. "Sustainability In The Life Sciences Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sustainability-in-the-life-sciences-industry-statistics.
Chicago
Kevin O'Brien. 2026. "Sustainability In The Life Sciences Industry Statistics." Gitnux. https://gitnux.org/sustainability-in-the-life-sciences-industry-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level